Elai Davicioni, PhD
President & CSO, Director

Elai DavicioniDr. Davicioni trained as a pathobiologist in the genomics laboratory of Professor Triche before becoming an entrepreneur, raising over $20M in grant funding and equity financing to launch GenomeDx. Elai’s research in cancer biology and bioinformatics in oncology with collaborators at the Children’s Oncology Group provided the experience for applying this know-how to other malignancies. Dr. Davicioni received his BSc in chemistry, MSc in biophysics at Ben Gurion University and PhD in pathobiology from the University of Southern California and previously worked in oncology biomarkers at Compugen, a leading Israeli computational biology company. At GenomeDx, Elai establishes collaborations with leading clinicians and researchers in urologic oncology to develop an ecosystem for genomics research and create a unique user experience for clinicians and patients using genomic information.

Doug Dolginow, MD
Medical Director

Doug DolginowDr. Dolginow is a board-certified clinical pathologist and experienced molecular diagnostics executive. Doug has been a founder and senior executive in numerous biotechnology and personalized medicine companies including Nichols Specialty Laboratories, OncoMed, GeneLogic and Veracyte. He has raised over $500M in financing and developed and executed business plans, strategic partnerships and deals for his companies. Dr. Dolginow received his BA from Harvard University and an MD from the University of Kansas. He has served as medical director for several clinical laboratories and is on the clinical faculty at the University of California, San Francisco. Doug’s vision in the personalized medicine arena is to build and grow innovative, capital-efficient companies to commercialize transformative medical products using genomic information.

Adam Chinnock
General Counsel and VP Legal Affairs

Mr. Chinnock has been our General Counsel and Vice President, Legal Affairs since October 2016. Prior to joining GenomeDx, Mr. Chinnock served in roles of increasing responsibility at Arena Pharmaceuticals, Inc., a publicly traded biotechnology company, from 2002 to August 2016, most recently as Vice President & Associate General Counsel, Corporate & Compliance. Prior to Arena, Mr. Chinnock was an attorney in the Business and Finance Group of Morgan, Lewis & Bockius LLP, an international law firm. Mr. Chinnock holds a B.A. in Economics, a B.A. in English and a J.D. from the University of California, Davis.